These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34035488)

  • 1. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes.
    Wu YL; Xue YR; Guo ZT; Chen ZD; Ge XY; Zhong DF; Diao XX
    Acta Pharmacol Sin; 2022 Mar; 43(3):747-756. PubMed ID: 34035488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer.
    Liu XY; Guo ZT; Chen ZD; Zhang YF; Zhou JL; Jiang Y; Zhao QY; Diao XX; Zhong DF
    Acta Pharmacol Sin; 2020 Oct; 41(10):1366-1376. PubMed ID: 32235864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
    Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
    Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo.
    Nilles J; Theile D; Weiss J; Haefeli WE; Ruez S
    Arch Toxicol; 2024 Aug; 98(8):2541-2556. PubMed ID: 38713375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
    Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling Å; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2020 Oct; 108(4):844-855. PubMed ID: 32320483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.
    Prueksaritanont T; Richards KM; Qiu Y; Strong-Basalyga K; Miller A; Li C; Eisenhandler R; Carlini EJ
    Pharm Res; 2005 Jan; 22(1):71-8. PubMed ID: 15771232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Suppression of CYP3A4 mRNA and Enzyme Activity by Epidermal Growth Factor in Plated Human Hepatocytes.
    Zhang JG; Wang D; Ho T; Clark RJ; Stresser DM
    Drug Metab Lett; 2017; 11(2):119-127. PubMed ID: 29189189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative.
    Luo G; Lin J; Fiske WD; Dai R; Yang TJ; Kim S; Sinz M; LeCluyse E; Solon E; Brennan JM; Benedek IH; Jolley S; Gilbert D; Wang L; Lee FW; Gan LS
    Drug Metab Dispos; 2003 Sep; 31(9):1170-5. PubMed ID: 12920173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.
    Hariparsad N; Nallani SC; Sane RS; Buckley DJ; Buckley AR; Desai PB
    J Clin Pharmacol; 2004 Nov; 44(11):1273-81. PubMed ID: 15496645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
    Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
    AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
    Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
    Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.
    Nallani SC; Glauser TA; Hariparsad N; Setchell K; Buckley DJ; Buckley AR; Desai PB
    Epilepsia; 2003 Dec; 44(12):1521-8. PubMed ID: 14636322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
    Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
    Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
    Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.
    Zuo R; Li F; Parikh S; Cao L; Cooper KL; Hong Y; Liu J; Faris RA; Li D; Wang H
    Drug Metab Dispos; 2017 Feb; 45(2):198-207. PubMed ID: 28062541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.
    Madan A; Graham RA; Carroll KM; Mudra DR; Burton LA; Krueger LA; Downey AD; Czerwinski M; Forster J; Ribadeneira MD; Gan LS; LeCluyse EL; Zech K; Robertson P; Koch P; Antonian L; Wagner G; Yu L; Parkinson A
    Drug Metab Dispos; 2003 Apr; 31(4):421-31. PubMed ID: 12642468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.
    Heng J; Tang Q; Chen X; Bao J; Deng J; Chen Y; Zhao J; Zhu S; Liu X; Yang F; Jiang Y; Yang N; Li K
    Eur J Pharm Sci; 2021 Jul; 162():105815. PubMed ID: 33771716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
    Li AP
    Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
    Liu X; Zhang Y; Chen Q; Zhan Y; Wang Q; Hu C; Yu C; Guo Z; Chen X; Zhong D
    J Clin Pharmacol; 2018 Mar; 58(3):347-356. PubMed ID: 28967981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.